Design of a platform technology for systemic delivery of siRNA to tumours using rolling circle transcription

Nature Communications

Volumn 6, Issue , 2015, Pages

  Jang, Mihue ^a   Kim, Jong Hwan ^a   Nam, Hae Yun ^b   Kwon, Ick Chan ^a   Ahn, Hyung Jun ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOFECTAMINE; NANOPARTICLE; SMALL INTERFERING RNA; CHOLESTEROL; DNA; FOLIC ACID; RNA;

CANCER; CATION; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; IMMUNE RESPONSE; METABOLISM; NANOPARTICLE; NANOTECHNOLOGY; POLYMER; RISK ASSESSMENT; RNA; TOXICITY; TUMOR;

ANIMAL EXPERIMENT; ARTICLE; CANCER LOCALIZATION; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA RNA HYBRIDIZATION; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NEOPLASM; NONHUMAN; RNA TRANSCRIPTION; ROLLING CIRCLE TRANSCRIPTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMISTRY; DRUG SCREENING; GENE SILENCING; GENETIC TRANSCRIPTION; NUDE MOUSE;

ANIMALS; CHOLESTEROL; DNA; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; GENE SILENCING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NANOPARTICLES; RNA; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938767300     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8930     Document Type: Article

References (48)

1. Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G. & Sood, A. K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 11, 59-67 (2011).
2. Schiffelers, R. M. et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149 (2004).
3. Yin, J. Q. et al. siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. J. Exp. Ther. Oncol. 3, 194-204 (2003).
4. Jiang, M. & Milner, J. Selective silencing of viral gene expression in HPVpositive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21, 6041-6048 (2002).
5. Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007 (2005).
6. Miller, V. M. et al. Allele-specific silencing of dominant disease genes. Proc. Natl Acad. Sci. USA 100, 7195-7200 (2003).
7. Wang, J., Lu, Z., Wientjes, M. G. & Au, J. L. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12, 492-503 (2010).
8. Tompkins, S. M., Lo, C. Y., Tumpey, T. M. & Epstein, S. L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl Acad. Sci. USA 101, 8682-8686 (2004).
9. Grzelinski, M. et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17, 751-766 (2006).
10. Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172-176 (2010).
11. Gillies, E. R. & Frechet, J. M. Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today 10, 35-43 (2005).
12. Malek, A. et al. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(PEG)/siRNA complexes. Toxicol. Appl. Pharmacol. 236, 97-108 (2009).
13. Moghimi, S. M. et al. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol. Ther. 11, 990-995 (2005).
14. Park, T. G., Jeong, J. H. & Kim, S. W. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 58, 467-486 (2006).
15. Lee, S. J. et al. Structural modification of siRNA for efficient gene silencing. Biotechnol. Adv. 31, 491-503 (2013).
16. Bolcato-Bellemin, A. L., Bonnet, M. E., Creusat, G., Erbacher, P. & Behr, J. P. Sticky overhangs enhance siRNA-mediated gene silencing. Proc. Natl Acad. Sci. USA 104, 16050-16055 (2007).
17. Mok, H., Lee, S. H., Park, J. W. & Park, T. G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat. Mater. 9, 272-278 (2010).
18. Lee, S. J. et al. Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew. Chem. Int. Ed. 51, 7203-7207 (2012).
19. Lee, J. B., Hong, J., Bonner, D. K., Poon, Z. & Hammond, P. T. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat. Mater. 11, 316-322 (2012).
20. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
21. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
22. Matsuda, S. et al. siRNA conjugates carrying sequentially assembled trivalent n-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10, 1181-7 (2015).
23. Cuellar, T. L. et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res. 43, 1189-1203 (2015).
24. Wan, C., Allen, T. M. & Cullis, P. R. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv. Transl. Res. 4, 74-83 (2014).
25. Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982-12987 (2007).
26. Aaldering, L. J. et al. Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy. RNA Biol. 12, 412-425 (2015).
27. Daly, T. A., Wang, M. & Regen, S. L. The origin of cholesterol's condensing effect. Langmuir 27, 2159-2161 (2011).
28. Springer, T., Sipova, H., Vaisocherova, H., Stepanek, J. & Homola, J. Shielding effect of monovalent and divalent cations on solid-phase DNA hybridization: surface plasmon resonance biosensor study. Nucleic Acids Res. 38, 7343-7351 (2010).
29. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discovery 9, 412-412 (2010).
30. Kariko, K., Bhuyan, P., Capodici, J. & Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172, 6545-6549 (2004).
31. Robbins, M., Judge, A. & MacLachlan, I. siRNA and innate immunity. Oligonucleotides 19, 89-102 (2009).
32. Jang, B. et al. Gold nanorods for target selective SPECT/CT imaging and photothermal therapy in vivo. Quant. Imaging Med. Surg. 2, 1-11 (2012).
33. Hu, X., Liu, S., Huang, Y., Chen, X. & Jing, X. Biodegradable block copolymerdoxorubicin conjugates via different linkages: preparation, characterization, and in vitro evaluation. Biomacromolecules 11, 2094-2102 (2010).
34. Falcone, S. et al. Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events. J. Cell Sci. 119, 4758-4769 (2006).
35. Curtin, F., Perron, H., Kromminga, A., Porchet, H. & Lang, A. B. Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. MAbs 7, 265-275 (2015).
36. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462 (2005).
37. Castanotto, D. & Rossi, J. J. The promises and pitfalls of RNA-interferencebased therapeutics. Nature 457, 426-433 (2009).
38. Robbins, M. et al. 20-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15, 1663-1669 (2007).
39. Mattheolabakis, G., Rigas, B. & Constantinides, P. P. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine 7, 1577-1590 (2012).
40. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature reviews. Drug Discovery 9, 615-627 (2010).
41. Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389-393 (2012).
42. Shopsowitz, K. E., Roh, Y. H., Deng, Z. J., Morton, S. W. & Hammond, P. T. RNAi-microsponges form through self-assembly of the organic and inorganic products of transcription. Small 10, 1623-1633 (2014).
43. Meyer, A., Auernheimer, J., Modlinger, A. & Kessler, H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12, 2723-2747 (2006).
44. Zhang, Y., Hong, H. & Cai, W. Tumor-targeted drug delivery with aptamers. Curr. Med. Chem. 18, 4185-4194 (2011).
45. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415 (2003).
46. Vlashi, E., Kelderhouse, L. E., Sturgis, J. E. & Low, P. S. Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumours. ACS Nano 7, 8573-8582 (2013).
47. Zuba-Surma, E. K. et al. Sca-1 expression is associated with decreased cardiomyogenic differentiation potential of skeletal muscle-derived adult primitive cells. J. Mol. Cell. Cardiol. 41, 650-660 (2006).
48. Dalby, B. et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33, 95-103 (2004).